Site search
2923 results for '' found
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures (NCT06908356)
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients with Focal Onset or Primary Generalized Tonic-Clonic Seizures (NCT06908356)
/
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy, Safety, and Tolerability of LP352 in the Treatment of Seizures in Children and Adults with
/
Expanded Access Program for Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies [DEEs] (NCT06149663)
Expanded Access Program for Treatment with LP352 for Patients with Developmental and Epileptic Encephalopathies [DEEs] (NCT06149663)
/
An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults with either classic Absence Epilepsy with or without Eyelid Myoclonia [EEM; Jeavons syndrome], O
An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults with either classic Absence Epilepsy with or without Eyelid Myoclonia [EEM; Jeavons syndrome], O
/
A Phase I/II, first-in-human, open-label, dose escalation and indication expansion study of the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of BNT3212 as monot
A Phase I/II, first-in-human, open-label, dose escalation and indication expansion study of the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of BNT3212 as monot
/
A Phase 1a/b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C0902, an Antibody-Drug Conjugate Targeting EGFR MET, Alo
A Phase 1a/b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C0902, an Antibody-Drug Conjugate Targeting EGFR MET, Alo
/
A Phase 1a/b Open-Label Master Study of PF-07799544 as a Single-Agent and in Combination with Other Targeted Agents in Participants with BRAF-Mutant Melanoma and Other Solid Tumors (NCT05538130)
A Phase 1a/b Open-Label Master Study of PF-07799544 as a Single-Agent and in Combination with Other Targeted Agents in Participants with BRAF-Mutant Melanoma and Other Solid Tumors (NCT05538130)
/
CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy [ATTR-CM] (NCT07207811)
CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy [ATTR-CM] (NCT07207811)
/
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease and/or Proximal Poplitea
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease and/or Proximal Poplitea
/
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis [IPF] (NCT06967805)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis [IPF] (NCT06967805)
/